Our Story

Founded in February 2025, PathoscribeAI was started by a group of AI specialists with a shared, strong interest in healthcare. Our founding principle was simple: advanced computation could dramatically improve and accelerate the long, costly process of drug development.

Our team combines deep expertise in machine learning, computational biology, and software engineering to build our intelligent platform. This system is designed to analyze complex datasets—from molecular structures to clinical trial results—to identify promising therapeutic candidates and novel biological targets.

We are driven by the challenge of applying technology to solve complex medical problems, both by finding new uses for existing medicines and by discovering new molecules for the treatments of the future.

Our Mission

Our core mission is to accelerate therapeutic discovery. We utilize advanced AI for both de novo drug design and high-throughput screening of repurposed compounds, aiming to shorten the R&D lifecycle and enhance preclinical success rates.

By applying in-silico analysis to complex biological data, we help pharmaceutical partners optimize their development pipelines and unlock the full potential of their molecular data assets.

Our Vision

We envision a future where AI-driven pharmacology is the standard, fostering an ecosystem of rapid innovation that expands the global therapeutic arsenal and streamlines the path from lab to clinic.

Our goal is to become the global leader in AI-powered drug discovery, playing a pivotal role in tackling critical diseases and fundamentally improving health outcomes for patients worldwide.